The cost of biosimilars might be greater than their reference brands for Medicare Part D beneficiaries who reach the coverage gap because of a provision in the Affordable Care Act.
The law exempts biosimilars from the 50% discounts manufacturers are required to provide on the negotiated price of branded drugs...